Method for the treatment of inflammatory disorders

Details Method for the treatment of inflammatory disorders Method for the treatment of inflammatory disorders

2008-11-11

2011-12-27

Haddad, Maher (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S152100, C530S388200

Reexamination Certificate

active

08084031

ABSTRACT:
A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.

REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5391481 (1995-02-01), Chess et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5788966 (1998-08-01), Chess et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5855888 (1999-01-01), Nishida et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6016159 (2000-01-01), Faris
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6127524 (2000-10-01), Casipit et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291650 (2001-09-01), Winter et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6303313 (2001-10-01), Wigler et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6326403 (2001-12-01), Holzemann et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6652856 (2003-11-01), Gotwals et al.
patent: 6955810 (2005-10-01), Gotwals et al.
patent: 7358054 (2008-04-01), Lyne et al.
patent: 7462353 (2008-12-01), Gotwals et al.
patent: 7723073 (2010-05-01), Karpusas et al.
patent: 7910099 (2011-03-01), Karpusas et al.
patent: 2010/0233159 (2010-09-01), Relton et al.
patent: 2011/0189177 (2011-08-01), Karpusas et al.
patent: 0 239 400 (1987-09-01), None
patent: 0239400 (1997-09-01), None
patent: 0 843 961 (1998-05-01), None
patent: 08-131185 (1996-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO9313798 (1993-07-01), None
patent: WO9417828 (1994-08-01), None
patent: WO9519790 (1995-07-01), None
patent: WO9711718 (1997-04-01), None
patent: WO9718838 (1997-05-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 00/20459 (2000-04-01), None
patent: WO 00/72881 (2000-12-01), None
patent: WO 01/73444 (2001-10-01), None
patent: WO 01/96365 (2001-12-01), None
Luque et al. Functional regulation of the human integrin VLA-1 (CD49a/CD29) by divalent cations and stimulatory β1 antibodies. FEBS Letters, vol. 346, Issues 2-3, Jun. 13, 1994, pp. 278-284.
Baldwin et al., “Cation binding to the integrin CD11b I domain and activation model assessment”Structure6:923-935 (1998).
Bank et al., “Analysis of Recombinant Human Integin Domain with a Function-Blocking Monoclonal Antibody 3.1”1stMed. Assoc. J. 2:19-20 (2000).
Bella Jordi, “Integrin-collagen complex:a metal glutamate handshake”Structure8(6):R121-R126 (2000).
Bennett et al., “Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody”Proc. Natl. Acad. Sci.USA80:2417-2421 (1983).
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes”J. Immunol. 147:86-95 (1991).
Border et al., “Transforming Growth Factor Beta in Tissue Fibrosis”New England J. Medicine331:1286-1292 (1994).
Bossy et al., “Characterization of the Integrin Alpha8 subnit: A new intefrin beta1-associated subunit, which is prominently expressed on axons and on cells in contact with basallaminaein chick embryos” EMBO J. 10:2375-2385 (1991).
Brezinsky et al., “A Simple Method of Enriching Populations of Transfected CHO Cells for Cells of Higher Specific Productivity”J. Immunol. Methods277:141-155 (2003).
Bridges et al., “Variable Region cDNA Sequences and Characterization of Murine Anti-Human Interferon γ Receptor Monoclonal Antibodies that Inhibit Receptor Binding by Interferon γ”Mol. Immunol. 32:1329-2989 (1995).
Briesewitz et al., “Expression of Native and Truncated Forms of the human integrin Alpha1 1 subunit*”J. Biol. Chemistry268:2989-2996 (1993).
Camper et al., “Isolation, Cloning, and Sequence Analysis of the Integrin Subunit a10, a Bet1-associated Collagen Binding integrin Expressed on Chondrocytes*”J. Biol. Chem. 273:20383-20389 (1998).
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89:4285-4289 (1992).
Cerf-Bensussan et al., “The human intraepithelial lymphocyte marker HML-1 is an integrin consisting of a Beta7 subunit associated with a distinctive alpha chain”Eur. J. Immunol. 22:273-277 (1992).
Chothia et al., “Conformations of Immunoglobulin Hypervariable Regions”Nature342:877-883 (1989).
Clackson et al., “Making antibody fragments using phage display libraries”Proc. Natl. Acad. Sci. USA352:624-628 (1991).
Co et al., “Humanized antibodies for antiviral therapy”Proc. Natl. Acad. Sci. USA88:2869-2873 (1991).
Colbert et al., “The effect of fluorescein labels on the affinity of antisera to small haptens”J. Imunol. Methods140:227-233 (1991).
Cook et al., “Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonaphritis”Am. J. Pathol. 161:1265-1272 (2002).
Corbi et al., “cDNA cloning and complete primary struction for the alpha subunit of a leukocyte adhesion glycoprotein”J. Biol. Chem. 263:12403-12411 (1987).
Corbi et al., The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) alpha SubunitJ. Biol. Chem. 263:12403-12411.
Cosgrove et al., “Integrin and Transforming Growth Factor-1 Play Distinct Roles in Alport Glomerular Pathogenesis and Serve as Dual Targets for Metabolic Therapy”Am. J. Path. 157:16498-1659 (2000).
Davies et al., “Interactions of Protein Antigens with Antibodies”Proc. Natl. Acad. Sci. USA93:7-12 (1996).
Davies, “The osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor”J. Cell Biology109:1817-1826 (1989).
de Fougerolles et al., “Global Expression Analysis of Extracellular Matrix-Integrin interactions in Monocytes”Immunity13:749-758 (2000).
de Fougerolles et al., “Regulation of Inflammation by Collagen-Binding Integrins and 1* in Models of Hypersensitivity and Arthritis”J. Clin. Invest. 105:721-729 (2000).
Diamond et al., “The I Domain Is a Major Recognition Site on the Luekocyte Integrin Mac-1 (CD-11b/CD18) for Four distinct Adhesion Ligands” 120:1031-1043 (1993).
Edwards et al., “Identification of Amino Acids in the CD11 a I-domain Important for Binding of the Leukocyte Function-associated Antigen-1 (LFA-1) to Intercellular Adhesion Molecules-1 (ICAM-1)*” J. Biol. Chem. 270:12635-12640 (1995).
Eigenbrot et al., “X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185HER2Antibody 4D5 and Comparison with Molecular Modeling”J. Mol. Biol. 229:969-995 (1993).
Emsley et al., “Crystal Structure of the I Domain from Integrin ”J. Biol. Chem. 272:28512-28517 (1997).
Emsley et al., “Structural Basis of Collagen Recognition by Integrin ”Cell100:47-56 (2000).
Fabbri et al., “A functional monoclonal antibody recognizing the human alpha1-integrin I-domain”Tissue Antigens48:47-51 (1996).
Fischmann et al., “Crystallographic Refinement of the Three-Dimensional Structure of the FabD1.3-Lysozyme Complex at 2.5-Å Resolution”J. Biol. Chem. 266:12915-12920 (1991).
Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”J. Mol. Biol. 224:487-499 (1992).
Gaspari et al., “Contact Hypersensitivity”Current Protocols in ImmunologyJ.E. Coligan et al., Editors, John Wiley & Sons, New York, Section 4.2.1-4.2.5 (1991).
Gotwals et al., “D

Affiliated with

Also associated with

Rating

Method for the treatment of inflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for the treatment of inflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of inflammatory disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309377